SCHEMBL23609142

SCHEMBL23609142

c1ccc(CNc2ccc(NCCn3cncn3)c(-c3ccccc3)n2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 2/20 0.41
LMNA P02545 3/20 0.39
MAPT P10636 3/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 5/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
HTT P42858 1/20 0.38
TP53 P04637 4/20 0.37
CYP1A2 P05177 2/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2D6 P10635 2/20 0.37
CLK4 Q9HAZ1 2/20 0.37
NFKB1 P19838 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
USP2 O75604 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30406536 0.86 NR1H4 (0.42) CYP19A1LMNAMAPTKDM4EMEN1
SCHEMBL23608978 0.82 SMN1; SMN2 (0.43) CYP19A1LMNAMAPTKDM4EMEN1
SCHEMBL23609257 0.81 KDM4E (0.41) CYP19A1LMNAMAPTKDM4EMEN1
SCHEMBL23608984 0.78 SMN1; SMN2 (0.44) CYP19A1LMNAMAPTKDM4EMEN1
SCHEMBL23609046 0.78 SMN1; SMN2 (0.44) CYP19A1LMNAMAPTKDM4EMEN1
SCHEMBL23608979 0.78 CYP19A1 (0.42) CYP19A1LMNAMAPTKDM4EMEN1
SCHEMBL23608999 0.78 CYP19A1 (0.43) CYP19A1LMNAMAPTKDM4EMEN1
SCHEMBL23608983 0.76 CYP19A1 (0.43) CYP19A1LMNAMAPTKDM4EMEN1
SCHEMBL23608965 0.73 CYP19A1 (0.41) CYP19A1LMNAMAPTKDM4EMEN1
SCHEMBL30406454 0.73 CYP1A2 (0.45) CYP19A1LMNAMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230117592-A1 LIPOXYGENASE INHIBITORS SRI INTERNATIONAL (US) 2023-04-20 US disclosed
WO-2021133689-A2 LIPOXYGENASE INHIBITORS SRI INTERNATIONAL (US) 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230117592-A1 LIPOXYGENASE INHIBITORS ALOX15B, ALOX12, ALOX5 CYP19A1 153/4885LMNA 1170/4885MAPT 2110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.